Allurion Technologies, Inc. pioneers metabolically healthy weight loss through its Allurion Program which combines a swallowable Procedureless intragastric balloon with an AI powered Virtual Care Suite. The Allurion Smart Capsule is placed during a brief outpatient visit without surgery endoscopy or anesthesia. The Virtual Care Suite provides remote patient monitoring behavior change tools and AI powered coaching to support patients and clinicians.

The company generates revenue primarily from sales of the Allurion Smart Capsule to health care providers. It sells the device through a direct sales force and through independent distributors in select international markets. Revenue may also be derived from subscription or service fees associated with the Virtual Care Suite platform.

Allurion Technologies, Inc. holds a differentiated position in the obesity treatment market as the developer of the world first swallowable Procedureless intragastric balloon. Compared with traditional balloons that require endoscopy and anesthesia its device demonstrates a lower serious adverse event rate and comparable or superior weight loss outcomes. The company benefits from a broad patent portfolio covering the capsule balloon fill and release mechanisms and the Virtual Care Suite software. Its competitive set includes other intragastric balloon manufacturers such as Boston Scientific Corporation (Apollo Endosurgery), ReShape Lifesciences (Medtimo) and Spatz FGIA Inc. as well as makers of GLP 1 receptor agonists like Novo Nordisk A/S and Eli Lilly & Co.

Allurion Technologies, Inc. serves health care providers such as clinics hospitals and physician practices that offer weight loss management programs. Its patients are adults who are overweight or obese seeking a non surgical option for weight reduction. The company does not disclose specific customer names in the filing.